Recent studies using various animal models of cancer have suggested a role for EPCs in tumor angiogenesis and growth [5, 6]. EPCs are present in the peripheral blood; in response to certain signals or cytokines, their levels are elevated and they are recruited into the neovascular bed of the tumor [7]. Emerging evidence suggests that changes in EPC levels may predict the efficacy of anticancer drug combinations that include antiangiogenic agents [8]. Although these data suggest a relationship between EPCs and tumor angiogenesis, the exact role of these cells in AZD8186 purchase the pathogenesis

of ovarian cancer has not been completely elucidated. The aim of this study was to determine the correlation between EPC levels and disease progression and angiogenesis in ovarian cancer. To that end, we quantified circulating EPCs from the peripheral blood of ovarian cancer patients by flow cytometry, before and after cancer treatment. In addition, we used real-time quantitative reverse transcription polymerase

chain reaction (RT-PCR) to evaluate mRNA levels of EPC-specific markers CD34 and vascular endothelial growth factor receptor 2 (VEGFR2) in the peripheral blood of ovarian cancer patients. Plasma RSL3 cell line protein levels of vascular endothelial growth factor (VEGF) and matrix metallopeptidase-9 this website (MMP-9) were also determined. Materials and methods Patients This study was approved by the local ethics committee, and informed consent was obtained from all study participants. Forty-two patients (median age, 43 years old; age range, 21-59 years old) with histologically proven ovarian cancer, including serous crotamiton cancer (n = 23), mucinous cancer (n = 13), and endometrioid cancer (n = 6), were included along with a control group of healthy women (n = 25, age range, 18-35 years old). Tumors were classified according to the 1987 staging criteria recommended

by the Federation of Obstetrics and Gynecology (FIGO). Of these patients, 30 patients underwent surgery for their malignancy, and 12 patients were treated with chemotherapy. These patients had no additional malignant, inflammatory, or ischemic disease, wounds, or ulcers that could influence the number of circulating EPCs. Peripheral blood samples of these patients were collected prior to treatment. All patients in this study received regular follow-up for 18 to 24 months (median follow-up, 20.2 months) after discharge. During this period, patients underwent physical examinations and related laboratory tests or imaging examinations once every 1 to 3 months. Blood samples were collected at 1 month after chemotherapy or surgery. Biological Samples and Flow Cytometric Analysis Analysis was based on the expression of surface markers CD34 and VEGFR2 on cells in the mononuclear gate where EPCs are commonly found. CD34+ and VEGFR2+ are commonly used as markers for EPCs [9–11].